Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

ClinicalTrials.gov ID: NCT06797362

Public ClinicalTrials.gov record NCT06797362. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Study identification

NCT ID: NCT06797362
Recruitment status: Available
Study type: Expanded access
Phase: Not listed
Lead sponsor: Nuvalent Inc.; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Interventions

NVL-520 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Not listed
Last update posted: Jun 14, 2026

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
University of Colorado Anschutz School of Medicine	Aurora	Colorado	80045	Available
University of Chicago Medical Center	Chicago	Illinois	60637	Available
Massachusetts General Hospital	Boston	Massachusetts	02114	Available
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Available
Memorial Sloan Kettering Cancer Center	Manhattan	New York	10065	Available
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Available
University of Washington / Fred Hutchinson Cancer Center	Seattle	Washington	98109	Available

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06797362, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 14, 2026 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06797362 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →